Last updated: May 24, 2026
Which companies are the suppliers for AMVUTTRA (viltolarsen)?
AMVUTTRA is marketed by ITF Therapeutics (formerly Italfarmaco/italfarmaco’s rare disease unit structure historically associated with AMVUTTRA commercialization), but the “supplier” concept in pharma splits into: (1) the manufacturer of record for drug substance (API), (2) the manufacturer of record for finished drug product, and (3) supply-chain vendors for raw materials and sterile vial fill-finish.
With no AMVUTTRA label-manufacturer details, Orange Book manufacturing sections, or drug substance supplier disclosures provided here, a complete, accurate supplier map cannot be produced.
What does the AMVUTTRA label say about manufacturer of record and drug substance sourcing?
Featured supplier answers normally come from the FDA-approved label sections that list:
- “Manufactured for” / “Distributed by”
- “Manufactured by” for the finished dosage form
- Sterile fill-finish sites (if disclosed)
- Sometimes a drug substance (“drug substance” is made by…) statement
No label text or specific FDA label manufacturer fields are included in the input, so supplier-of-record identification cannot be completed.
What are the AMVUTTRA (viltolarsen) FDA Orange Book listings and what do they imply for supply?
Orange Book listings often indicate:
- Application/approval number
- Patent-protected items
- In some cases, information that helps match product to specific manufacturing sites via labeling and application references
No Orange Book entry content (ANDA/BLA, listed patents, application holder, and manufacturing/labeling cross-references) is provided, so the supplier inference path is unavailable.
What manufacturing steps for AMVUTTRA constrain supplier qualification?
AMVUTTRA is an injectable anti-sense oligonucleotide (single-stranded RNA/DNA analog class). Supply is constrained by:
- Controlled synthesis of oligonucleotide sequence starting blocks
- Purification and characterization (impurity profile)
- Sterile drug product manufacturing and fill-finish under aseptic processing
- Oligonucleotide-specific raw material availability (nucleoside building blocks, reagents)
- Analytical release testing and stability programs
However, without disclosed manufacturing site names, cGMP details, or supplier contracts, the constrained supply-chain vendor list cannot be stated as facts.
Which Paragraph IV or exclusivity issues affect who can supply AMVUTTRA?
AMVUTTRA is not a small-molecule with easy generic routes; oligonucleotide injectables face:
- Formulation/process patent barriers
- Analytical comparability burdens
- Potential exclusivity blocking additional approvals during the protection window
No protection timeline, listed exclusivity, or relevant patent estate is provided in the prompt, so it is not possible to tie “who can supply” to “what is legally allowed” in a precise way.
How many supplier sites are typically used for AMVUTTRA-like oligonucleotide injectables?
For oligonucleotide injectables, typical supply arrangements include:
- One API site
- One drug product aseptic fill-finish site (may be split)
- Qualified secondary suppliers for sterile components (vials, stoppers) and buffers
But “typical” is not a substitute for “what AMVUTTRA uses.” No company names or site identifiers are available in the input.
Key Takeaways
- AMVUTTRA supplier mapping requires manufacturer-of-record and/or drug substance supplier disclosures (FDA label and Orange Book manufacturing references).
- The prompt provides no label or Orange Book data, so naming specific supplier companies would be guesswork.
- A fact-complete supplier list for AMVUTTRA cannot be produced from the provided information alone.
FAQs
- Who is the manufacturer of record for AMVUTTRA?
- What companies supply viltolarsen drug substance (API) for AMVUTTRA?
- Which contract manufacturing organizations (CMOs) perform AMVUTTRA sterile fill-finish?
- Are there alternative suppliers for AMVUTTRA components (vials, stoppers, sterile fill materials)?
- How do AMVUTTRA patent and exclusivity protections limit who can become an approved supplier?
References
No sources were provided in the prompt.
